REPORT – This disease, which leads to vision loss, affects a quarter of those over 75 years of age. Every day at the Paris Hospital des Quinze-Vingts, 80 patients receive treatment directly injected into the eye to slow their progress.
A spring morning at the Quinze-Vingts National Hospital in Paris. The man who has been waiting for a few minutes in a small waiting room on the ground floor, in his sixties, seems stressed. Sitting in a seat, he twists his hands in all directions, looking anxiously at the door in front of him. This morning he must receive his very first injection against the age-related macular degeneration (DMLA) that attacks one of his eyes. The door abruptly opens on a nurse: “Come on, let’s go!».
Behind her, in what looks like a mini-operating room, a green-clad surgeon prepares a syringe. For long minutes, the doctor and nurse carefully disinfect the patient’s previously anesthetized eye, before gently pushing the needle – very thin – into it. «It’s always impressive the first time, many patients fear that their eyes will be punctured. But in reality it is harmless and completely painless
This article is for subscribers only. You have 87% left to discover.
Pushing the limits of science is also freedom.
Keep reading your article for € 0.99 the first month
Already a subscriber?
Log in
.